NATCO PHARMA
Back to Income Statement
|
NATCO PHARMA Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹4,430 Cr | ₹3,999 Cr | ₹2,707 Cr | ₹1,945 Cr | ₹2,052 Cr |
What is the latest Revenue of NATCO PHARMA ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹4,430 Cr |
| Mar2024 | ₹3,999 Cr |
| Mar2023 | ₹2,707 Cr |
| Mar2022 | ₹1,945 Cr |
| Mar2021 | ₹2,052 Cr |
How is Revenue of NATCO PHARMA Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹4,430 Cr | 10.77 | |
| Mar2024 | ₹3,999 Cr | 47.72 | |
| Mar2023 | ₹2,707 Cr | 39.20 | |
| Mar2022 | ₹1,945 Cr | -5.23 | |
| Mar2021 | ₹2,052 Cr | - | |
Compare Revenue of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹17,546.4 Cr | 5.6% | 15% | -1.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹461,644.0 Cr | 1.2% | 8.3% | 15.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹184,053.0 Cr | -0.2% | 3% | -0.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹167,464.0 Cr | 1.7% | 9.9% | 46.8% | Stock Analytics | |
| CIPLA | ₹115,263.0 Cr | -2.2% | 4.5% | -4.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,049.0 Cr | -9% | -2.1% | -1.8% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | 5.6% |
15% |
-1.2% |
| SENSEX | -0.9% |
4.9% |
-6.8% |
You may also like the below Video Courses